TY  - JOUR
AU  - Bernabéu, Ignacio
AU  - Fajardo, Carmen
AU  - Marazuela, Mónica
AU  - Cordido, Fernando
AU  - Venegas, Eva María
AU  - de Pablos-Velasco, Pedro
AU  - Maroto, Gonzalo Piedrola
AU  - Olvera, María Pilar
AU  - de Paz, Isabel Pavón
AU  - Carvalho, Davide
AU  - Romero, Carme
AU  - De la Cruz, Guillermo
AU  - Escolá, Cristina Álvarez
PY  - 2020
DO  - 10.1007/s12020-020-02424-z
UR  - http://hdl.handle.net/10668/16023
T2  - Endocrine
AB  - Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin...
LA  - en
KW  - Acromegaly
KW  - Growth hormone
KW  - Insulin-like growth factor 1
KW  - Lanreotide
KW  - Somatostatin
KW  - Acromegaly
KW  - Cross-Sectional Studies
KW  - Delayed-Action Preparations
KW  - Human Growth Hormone
KW  - Humans
KW  - Insulin-Like Growth Factor I
KW  - Middle Aged
KW  - Peptides, Cyclic
KW  - Quality of Life
KW  - Somatostatin
TI  - Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.
TY  - research article
VL  - 70
ER  -